Triple Play Biotech Company: Sunshine Biopharma (Stock Symbol: Sbfm) Is A Company Working In The High Value Sectors Of Cancer Treatments, Science Based Nutritional Supplements And A Vitally Needed Anti Coronavirus Drug
December 1, 2020 (Viz Release) – – SBFM is a Company Working in the High Value Sectors of Cancer Treatments, Science-Based Nutritional Supplements & a Vitally Needed Anti-Coronavirus Drug
– Biopharma Company with Worldwide Patents on Effective Cancer Drugs.
– Joint Agreement to Advance Cancer Treatment to Clinical Trials in Canada.
– New Distribution of Nutritional Supplements in Asia and the Far East.
– Developing New Anti-Coronavirus Drug with the University of Georgia.
– $2 Million Financing in Place to Support Anti-Coronavirus Program.
Sunshine Biopharma (OTC: SBFM) is a pharmaceutical company focused on the research, development, and commercialization of oncology and antiviral drugs. In addition, SBFM is engaged in the development and commercialization of science-based nutritional supplements and is also currently engaged in the development of a new pharmaceutical to treat infections of the Covid-19 Coronavirus.
Since inception, SBFM has been involved in the development of Adva-27a, a small molecule that has been shown to be exceptionally effective at destroying Multidrug Resistant Cancer Cells, including Pancreatic Cancer cells (Panc-1), Small-Cell Lung Cancer cells (H69AR), Breast Cancer cells (MCF-7/MDR) and Uterine Sarcoma cells (MES-SA/Dx5). SBFM is a direct owner of all worldwide patents covering Adva-27a, including all issued and pending patents.
– Agreement with a Montreal-based Company to Advance the Highly Promising Development of Adva-27a Anticancer Compound
On November 18th SBFM announced a collaboration agreement with a Montreal-based company for the purposes of advancing the development of the SBFM anticancer compound, Adva-27a. The goal of this collaboration is to develop and implement chemical synthesis procedures for Adva-27a and test the resulting material in various types of cancer cells grown in culture. Based on the cell culture results, the SBFM drug development partner will conduct mice studies in preparation for entry of Adva-27a into clinical trials. It is anticipated that the clinical trials will be for Stage IV pancreatic cancer indication and will be performed at McGill University’s Jewish General Hospital in Montreal, Canada.
– Distribution of High Value Essential-9(TM) in Asia and the Far East
On November 10th SBFM announced an agreement with JOAH International Pte., Ltd., headquartered in Singapore, for distribution of Essential-9tm in Asia and the Far East. The SBFM Essential-9tm is a nutritional supplement tablet comprised of a balanced formula of the 9 essential amino acids that the human body cannot make. Essential-9tm is authorized for marketing by Health Canada under NPN 80089663.
Essential Amino Acids are 9 out of the 20 amino acids required for protein synthesis. Proteins are involved in all body functions – From the musculature and immune system to hormones and neurotransmitters. Like vitamins, Essential Amino Acids cannot be made by the human body and must be obtained through diet. Deficiency in one or more of the 9 Essential Amino Acids can lead to loss of muscle mass, chronic fatigue, weight gain, and weakened immune system. The SBFM Essential-9TM provides a balanced formula of all 9 Essential Amino Acids in free-form, ready to be absorbed. Essential-9tm is suitable for everyone: Vegans, Seniors, Dieters, Athletes, and everyone looking to increase their health. In North America, Essential-9tm is available on Amazon.com and Amazon.ca.
– Sunshine Biopharma and the University of Georgia Team Up to Develop New and Vitally Needed Anti-Coronavirus Drug
On October 19th SBFM announced an agreement with the University of Georgia to advance the development of the company’s recently announced Anti-Coronavirus lead compound, SBFM-PL4. The goal of this cutting-edge collaboration is to develop SBFM-PL4, a protease inhibitor, as a treatment for Coronavirus infections. This new treatment is based on the technology described in recently filed SBFM patent application covering small molecules which can be used to treat Coronavirus infections. Sunshine’s SBFM-PL4, will be put through a series of in vitro tests to evaluate its specific inhibitory activity against the SARS-CoV-2 papain-like protease (PLpro), one of two Coronavirus encoded proteases essential for viral replication. Following the initial in vitro studies, SBFM-PL4 will be moved forward to the cell culture testing stage and assessment in Coronavirus infected mice before entering human clinical trials.
Severe Acute Respiratory Syndrome-Coronavirus-2 (SARS-CoV-2) is the causative agent of COVID-19, the current pandemic. There are currently no drugs that can effectively arrest replication of the virus in people who have contracted the illness. On May 22nd SBFM filed a provisional patent application for a library of molecules which were designed to inhibit the Coronavirus proteases, thus shutting down the ability of the virus to multiply and cause illness.
– Sunshine Biopharma Secures $2,000,000 + Financing for Critical Coronavirus Treatment
On September 15th SBFM announced that it has received the first tranche of $250,000 as part of a committed minimum financing of $2 Million with RB Capital Partners Inc. Under the agreement RB Capital has agreed to provide funding to SBFM in the form of convertible promissory notes (the “Promissory Notes”). The Promissory Notes will bear interest at the rate of 5% per annum and will be fully convertible into shares of the Company’s Common Stock at a conversion price equal to the market value on the applicable conversion date or $0.30 per share, whichever is greater. The Promissory Notes will have a maturity date of two years from the date of issuance and must be fully converted on or before the maturity date. SBFM reserves the right to pay off any part or all of the Promissory Notes at any time without penalty. The minimum amount of funding that RB Capital has agreed to provide to SBFM under these terms is $2,000,000, payable over the next three to six month period.
The proceeds will be used for development of the SBFM Coronavirus treatment on a priority basis and the clinical development of Adva-27a, the Company’s flagship anticancer compound targeted for pancreatic cancer.
For more information on Sunshine Biopharma (OTC: SBFM) visit: http://www.sunshinebiopharma.com
DISCLAIMER: CorporateAds.com (CA) is a third-party publisher and news dissemination service provider. CA is NOT affiliated in any manner with any company mentioned herein. CA is news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. CA’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release or opinion of the writer. CA is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. CA has been compensated $400.00 for this release and HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company’s current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies’ contracts, the companies’ liquidity position, the companies’ ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur.